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1. Introduction {#jia225193-sec-0004}
===============

Successful antiretroviral therapy (ART) suppresses HIV viral load, reduces the incidence of new infections and increases the life expectancy of infected individuals [1](#jia225193-bib-0001){ref-type="ref"}, [2](#jia225193-bib-0002){ref-type="ref"}, [3](#jia225193-bib-0003){ref-type="ref"}, [4](#jia225193-bib-0004){ref-type="ref"}, [5](#jia225193-bib-0005){ref-type="ref"}. However, HIV drug resistance (HIVDR) can occur as result solely from poor proof‐reading during viral replication or the combined effect from poor proof‐reading and drug selection during unsuccessful ART [6](#jia225193-bib-0006){ref-type="ref"}, [7](#jia225193-bib-0007){ref-type="ref"}. With drastic increase in ART coverage worldwide, HIVDR has become a major barrier that hinders its effectiveness [8](#jia225193-bib-0008){ref-type="ref"}. Conventional HIVDR genotyping qualitatively detects drug resistance mutation (DRM) using Sanger sequencing approaches, which has limited capacity in reliable detection of minority variants present at frequencies below approximately 20%, with potentially relevant clinical impact [9](#jia225193-bib-0009){ref-type="ref"}, [10](#jia225193-bib-0010){ref-type="ref"}, [11](#jia225193-bib-0011){ref-type="ref"}.

Next‐generation sequencing (NGS), as exemplified by Illumina sequencing‐by‐synthesis technology, refers to newer sequencing technologies that enable high‐throughput, massively parallel sequencing of individual input templates [11](#jia225193-bib-0011){ref-type="ref"}, [12](#jia225193-bib-0012){ref-type="ref"}, [13](#jia225193-bib-0013){ref-type="ref"}. When applied to HIVDR genotyping, such technologies bestow unique advantages and significantly improve sensitivity for resolving complex HIV quasispecies with exceptional resolution and quantitative minority variant identification [11](#jia225193-bib-0011){ref-type="ref"}, [13](#jia225193-bib-0013){ref-type="ref"}, [14](#jia225193-bib-0014){ref-type="ref"}. The high scalability and ongoing cost reduction of NGS also permit further improvement in time efficiency and cost‐effectiveness of NGS HIVDR assays when many batched specimens are being processed [15](#jia225193-bib-0015){ref-type="ref"}, [16](#jia225193-bib-0016){ref-type="ref"}, [17](#jia225193-bib-0017){ref-type="ref"}. While broader adoption in testing laboratories could lead to new NGS‐based standards for HIVDR genotyping, some important issues remain to be addressed, including lack of standardization for NGS HIVDR data analysis pipelines and resulting accurate and meaningful low‐abundance variant data interpretation [11](#jia225193-bib-0011){ref-type="ref"}, [13](#jia225193-bib-0013){ref-type="ref"}, [18](#jia225193-bib-0018){ref-type="ref"}.

Like other molecular assays, the routine use of NGS HIVDR assays requires fully validated protocols that dictate sample processing in the laboratory. However, NGS also requires well‐defined bioinformatics strategies and tools that help to reliably convert raw NGS data into user‐interpretable HIVDR results. Notably, with the broad adoption of NGS, the sequencing itself has become relatively less challenging, while the data processing steps have become the primary bottleneck for its generalized application to HIVDR. Such challenges arise largely from: (1) high HIV sequence diversity [19](#jia225193-bib-0019){ref-type="ref"}; (2) unprecedented large volume of NGS data, (3) sequence‐specific errors, some of which are intrinsic to different NGS platforms [20](#jia225193-bib-0020){ref-type="ref"}, [21](#jia225193-bib-0021){ref-type="ref"}; (4) relatively short NGS read lengths with suboptimal basecalling accuracies; and (5) requirement for advanced bioinformatics skills and high performance computing capacity. Most NGS software applications are designed for the analysis of organismal genomes of a fixed ploidy and having modest sequence coverage. In contrast, the HIV genome exists as a quasispecies, and thus presents unique challenges for its sequencing and analysis. Existing NGS analysis pipelines for HIVDR to date have been developed by independent research groups with little coordination or any pre‐existing guidelines to reference, and thus differ in their data processing strategies and their output formats (Table [1](#jia225193-tbl-0001){ref-type="table"}). This lack of conventions to which to adhere leads to uncertainties in data reliability and also makes the comparison of outputs from different pipelines unnecessarily difficult [11](#jia225193-bib-0011){ref-type="ref"}. Moreover, it also impedes the ability of regulatory agencies to standardize and benchmark such assays for accreditation purposes. Thus, a consensus recommendation on standards for bioinformatic analysis and reporting conventions for HIVDR research and clinical purposes is urgently required.

###### 

Currently available pipeline/software for automated NGS‐based HIVDR data analysis

  Pipeline/software                                                                                          Reference information                                      Resources   Technical characteristics                       HIV drug resistance   HIVDR data analysis features                                                                                                                            
  ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- ----------- ----------------------------------------------- --------------------- ------------------------------ ---------------------- --------------------------------------------- ----- ----- ------------ ------------------ ------- -----
  V‐Phaser 2 [40](#jia225193-bib-0040){ref-type="ref"}                                                       https://www.broadinstitute.org/viral‐genomics/v‐phaser‐2   2013        Free                                            N/A                   Yes                            N/A                    No                                            No    No    No           csv/*csv*          E       Yes
  ShoRah [41](#jia225193-bib-0041){ref-type="ref"}                                                           https://github.com/cbg‐ethz/shorah                         2013        Free                                            N/A                   Yes                            N/A                    No                                            No    No    No           csv/*N/A*          E       N/A
  VirVarSeq [42](#jia225193-bib-0042){ref-type="ref"}                                                        https://sourceforge.net/projects/virtools/                 2015        Free                                            N/A                   Yes                            Illumina               No                                            No    No    No           fasta/*csv*        Q/E     Yes
  MinVar [43](#jia225193-bib-0043){ref-type="ref"}                                                           <https://ozagordi.github.io/MinVar/>                       2016        Free                                            \<1 hour              Yes                            Illumina               Yes[k](#jia225193-note-0002){ref-type="fn"}   No    Yes   HIVdb        vcf/*csv*          Q       Yes
  V‐pipe                                                                                                     https://cbg‐ethz.github.io/V‐pipe/                         2017        Free                                            N/A                   Yes                            Illumina               No                                            No    No    No           fasta/csv          Q       Yes
  Hivmmer [44](#jia225193-bib-0044){ref-type="ref"}                                                          https://github.com/kantorlab/hivmmer                       2017        Free                                            \<1 hour              Yes                            Illumina               No                                            No    Yes   No           csv/*csv*          L       Yes
  Geno2Pheno\[ngs‐freq\][45](#jia225193-bib-0045){ref-type="ref"} [a](#jia225193-note-0002){ref-type="fn"}   <http://ngs.geno2pheno.org/>                               2018        Free                                            \<1 minute            Yes                            N/A                    No                                            Yes   Yes   g2p\[res\]   fasta/*csv*        N/A     Yes
  MiCall[b](#jia225193-note-0002){ref-type="fn"}                                                             https://github.com/cfe‐labMiCall                           2016        Free                                            \<1 hour              No                             Illumina               Yes                                           Yes   Yes   HIVdb        Csv/*csv*          Q/E     Yes
  HyDRA                                                                                                      <https://hydra.canada.ca>                                  2016        Free                                            \<1 hour              No                             Illumina Ion Torrent   No                                            Yes   Yes   HIVdb        fasta,vcf/*aavf*   Q/E     Yes
  PASeq.org                                                                                                  <https://www.paseq.org>                                    2016        Free                                            \<1 hour              No                             Illumina               Yes                                           Yes   Yes   HIVdb        fasta/*csv*        Q/C/A   Yes
  DeepChek HIV [46](#jia225193-bib-0046){ref-type="ref"}                                                     <https://www.ablsa.com/overview/deepchek/>                 2014        \$65[l](#jia225193-note-0002){ref-type="fn"}    \<1 hour              No                             Illumina Ion Torrent   Yes                                           Yes   Yes   HIVdb        csv/*csv*          Q       Yes
  Smart GeneHIV                                                                                              <http://www.smartgene.com/mod_ngs.html>                    2016        N/A                                             N/A                   No                             N/A                    No                                            Yes   Yes   HIVdb        N/A                N/A     Yes
  Vela sentosa HIV [47](#jia225193-bib-0047){ref-type="ref"}                                                 <http://www.veladx.com/HIV.html>                           2016        \$200[m](#jia225193-note-0002){ref-type="fn"}   N/A                   No                             Ion Torrent            No                                            Yes   Yes   HIVdb        fasta/*csv*        Q       Yes
  Hyrax Exatype                                                                                              https://exatype.com/                                       2018        N/A                                             \<1 hour              No                             Illumina IonTorrent    Yes                                           Yes   Yes   HIVdb        fasta/*csv*        Q       Yes

The pipelines/software are categorized as: (1) freely available software for bioinformaticians (top block); (2) freely available software suitable for non‐bioinformaticians (middle block); and (3) commercial software (bottom block). Within each block, the chronological order was followed. N/A**,** Information not available or not applicable. NGS, next‐generation sequencing; HIVDR, HIV drug resistance.

^a^Geno2pheno\[ngs‐freq\] pipeline can only use a codon frequency table as an input which needs to be obtained separately; ^b^pending approval and release on Illumina BaseSpace Sequence Hub. For early access, please <micalldev@cfenet.ubc.ca>; ^c^year of publication/*public availability*; ^d^approximate per sample cost of bioinformatic data analysis only; ^e^time range for single sample data analysis (data transfer time excluded); ^f^refers to the need of on‐site computational infrastructure or expert staff; ^g^Ref DB and algorithm: reference HIV resistance database and/or algorithms for HIV resistance interpretation *(HIVdb: Stanford HIV Database)*; g2p\[res\] refers to the Geno2pheno\[resistance\] statistical engine; ^h^output: format of output files reporting nucleotide (nt) and amino acid (aa) variations; ^i^QA check strategies incorporated for NGS read quality assurance (Q: Quality Control; C: Contamination Control; E: Sequencing Error Model; L: Alignment Quality Filter; A: ApoBEC Hypermutation Detection); ^j^indels are recognizable by default but no codon‐aware strategies are implemented for reporting insertion/deletion mutations specifically associated to HIV resistance; ^k^can be ported to Cloud; ^l^cost based on general access through Illumina basespace; ^m^approximate cost of whole sample analysis (sample preparation, sequencing, data analysis).
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Development of such a consensus necessitates knowledge of NGS data characteristics, relevant bioinformatics skill sets, appreciation of the clinical relevance (or lack thereof) of minority variants and, importantly, extensive expertise and experience in performing NGS HIVDR data analysis. In this commentary, we report the outcome of an international symposium on bioinformatic strategies for NGS HIVDR testing, which was held in February 2018 in Winnipeg, Canada, convening bioinformaticians, scientists and clinicians from four NGS HIVDR pipeline teams, including: HyDRA from the National Microbiology Laboratory in Canada, PASeq.org from Institute for AIDS Research (IrsiCaixa) in Spain, MiCall from the British Columbia Centre for Excellence in HIV/AIDS in Canada and hivmmer from the Providence‐Boston Center for AIDS Research at Brown University in USA. Notably, HyDRA, PASeq.org and MiCall are freely available web interfaces and are used by many investigators worldwide, while hivmmer and several other pipelines are also freely available but still require advanced computational skills to execute (Table [1](#jia225193-tbl-0001){ref-type="table"}). In‐depth discussions and brainstorming sessions were organized during the symposium. The consensus for NGS‐based HIVDR data analysis that was reached among the participating groups (referred to as the "Winnipeg Consensus" hereafter) is summarized and presented here. It is noteworthy that all bioinformatics strategies discussed at the symposium and presented in this "Winnipeg Consensus" are based on the second‐generation sequencing technologies exemplified by Illumina sequence‐by‐synthesis technology.

2. Discussion {#jia225193-sec-0005}
=============

The characteristics of an optimal NGS HIVDR data processing pipeline include: (1) automated data analysis with a short turnaround time; (2) accommodation of all relevant HIV genes and raw data from varied NGS platforms; (3) incorporation of essential quality assurance (QA)/quality control (QC) strategies to ensure data accuracy and reproducibility; (4) production of customizable and easy‐to‐interpret HIVDR reports that satisfy research, surveillance and clinical monitoring needs; (5) user‐friendliness requiring minimal or no bioinformatics experience; and (6) easy access with minimal additional cost to the end‐users. The Winnipeg Consensus covers the major bioinformatic strategies that help to satisfy these requirements.

Although pipelines vary, some basic principles apply in NGS HIVDR data analysis. The analytic components of an NGS HIVDR pipeline were grouped into five sequential functional blocks: (1) NGS read QC/QA; (2) NGS read alignment and reference mapping; (3) HIV variant calling and variant QC; (4) HIVDR interpretation and reporting; and (5) analysis data management. Table [2](#jia225193-tbl-0002){ref-type="table"} details the Winnipeg Consensus on the major functionalities in each of these blocks, including analysis objectives, consensus on strategies and associated considerations, where applicable. The highlights include:

###### 

Outcomes of the Winnipeg Consensus for recommended bioinformatic strategies for an NGS‐based HIVDR data analysis pipeline

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Functional blocks                                                                           Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Consensus on strategies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Notes and comments
  ------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1\. NGS read quality control/quality assurance                                              To ensure only quality reads are applied in downstream data processing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            1\. Average quality score (QS) of the read: 25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 A QS at 25 corresponds to an estimated sequencing error rate of 0.3% [48](#jia225193-bib-0048){ref-type="ref"}. When possible, direct QS examination for all individual bases and exclusion of those with scores \<25 from subsequent analysis are recommended

  2\. Minimum read length: 75 bases                                                           This is based on Illumina 300‐cycle paired‐end sequencing and it may vary if another NGS platform or sequencing protocol is applied                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  3\. Contamination check: recommended                                                        External non‐viral contamination may be interfering with HIV NGS efficiency. HIV cross‐sample contamination or "index hopping" implies errors in laboratory sample processing which may lead to erroneous minority variant detection (see strategies implemented in V‐Pipe and ViCroSeq\[<https://github.com/mnoguera/ViCroSeq>\] tools) [49](#jia225193-bib-0049){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  4\. APOBEC mutation check: recommended                                                      Presence of APOBEC‐edited DNA templates in the sequenced sample may result in the artefactual detection of minority variant related to APOBEC activity. Filtering this non‐viable sequence content is beneficial especially when significant amounts of HIV proviral DNA may be present in the input specimen (i.e. PBMC, dried blood spots) [50](#jia225193-bib-0050){ref-type="ref"}, [51](#jia225193-bib-0051){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  2\. NGS read alignment and reference mapping                                                To ensure the efficiency and accuracy of NGS read alignment to reference sequences                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1\. HIV‐1 reference: HXB‐2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     For conserved regions such as HIV‐1 *pol*, the choice of reference has minimal impact on subsequent alignment to a single reference. HXB‐2 is a natural choice for the reference sequence since it provides the standard coordinate system for reporting DRMs. Iterative realignment to a sample‐specific consensus may also reduce the importance of the initial choice of reference sequence. However, for variable regions such as *env*, a more comprehensive collection/database of reference sequences should be evaluated

  2\. NGS read aligner: short‐read aligner is recommended                                     Bowtie2 is thus far the most commonly used NGS short‐read aligner due to its speed, availability, documentation, ease of installation and active maintenance [26](#jia225193-bib-0026){ref-type="ref"}. An alternative to NGS short‐read alignment is to conduct probabilistic multiple‐sequence alignment with HMMER [52](#jia225193-bib-0052){ref-type="ref"}. Other aligners and alignment strategies that have been previously evaluated by the group but are no longer in use include SMALT, BWA‐MEM, BLAST [53](#jia225193-bib-0053){ref-type="ref"}, custom implementations of codon‐aware Smith--Waterman alignment [54](#jia225193-bib-0054){ref-type="ref"}, MOSAIK [55](#jia225193-bib-0055){ref-type="ref"}, stampy [56](#jia225193-bib-0056){ref-type="ref"} and SHRiMP2 [57](#jia225193-bib-0057){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  3\. Analysis of whole *pol* gene: required                                                  Coverage of the entire *pol* region is required to enable HIVDR analysis on all genes encoding the three ART‐targeted enzymes (protease, reverse transcriptase and integrase)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  4\. Indel management: required                                                              Effective indel management strategy (i.e. codon‐aware alignments) is not available in existing pipelines. However, with several indel variations contributing to HIVDR, full‐codon indels should be properly identified and reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  3\. HIV variant calling and variant quality control                                         To ensure the accuracy of variant calling                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         1\. QC/QA of nucleotide variant calling: recommended                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Additional QA/QC procedures may be incorporated to further ensure the variant call accuracy. For instance, HyDRA calls variation only when minimum allele counts is ≥5, minimum QS of variant allele is ≥30 and read depth at the relevant variation site is ≥100

  2\. Amino acid variation calling based on NGS reads, but NOT consensus sequence: required   Consensus sequence‐based DRM analysis renders inevitable assumption while ≥2 mixed bases present in the codon, which diminishes NGS values in quantitative DRM detections                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  3\. Secondary QC for minority variant calling: optional                                     It helps to exclude erroneous variant calls via statistical estimation based on gross platform‐specific error rate, as determined by parallel sequencing of pedigreed plasmid in the NGS run, which sums all potential errors from any involved assay procedures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  4\. HIVDR interpretation and reporting                                                      HIVDR interpretation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Query reference database and algorithms: HIVdb (<https://hivdb.stanford.edu>)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Although minor discrepancies exist with other alike databases, Stanford database (HIVdb) is recommended for better general adoption

  Concise report *(for potential clinical use)*                                               The report should contain the following: Patient and sample information if provided (optional)Exportable/printable HIVDR report with DRMs and colour‐coded resistance interpretationsTwo‐column summary on DRMs at reporting threshold of 5% and 15% respectively with no detailed frequenciesPipeline and software version appliedComment on the accreditation status of the assay for clinical use                                                                                                                                                                                                                                                                                                                                                                                                                              Concise HIVDR reports from NGS data should simulate Sanger sequencing output for easier adoption and interpretation by clinicians, to be used for clinical care\                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Integrase gene should be examined in addition to reverse transcriptase and protease and samples with no integrase data should be flagged\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                The reporting thresholds are suggested to simulate sensitivity of SS in DRM detection (15%) and to exemplify a practical threshold for reporting authentic DRMs of potential clinical relevance with minimal interference from errors/bias (5%). Further refinement of these values may be required as relevant research advances                                                                                                                                                                                                                                                                                                              

  Comprehensive report *(for research use)*                                                   The report should contain the following: All contents included in clinical reports.Summary on filtering statistics, quality metrics and coverage plotsQuantitative report on all HIV‐1 DRMs with exact frequenciesConsensus sequence with threshold of 15% for mixed base call                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Comprehensive reports should contain all NGS‐derived data that researchers may utilize for various application purposes\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Customizable HIVDR reporting is encouraged to enable users to construct report that best serves their needs. For instance, a customizable frequency threshold setting for DRM identification and reporting and user‐definable threshold(s) for consensus sequence generation are recommended                                                                                                                                                                                                                                                                                                                                                   

  Other exportable data *(Optional)*                                                          Consensus sequences with user‐defined threshold: recommendedVariant reports on all nucleotide loci: recommendedVariant reports on all amino acid loci: recommendedCodon usage at all amino acid variations loci: recommended                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Standard VCF/BCF format is recommended for nucleotide variant reports. To facilitate comparisons and merging of data from different pipelines, a new standard .aavf reporting format is proposed (Appendix* * [1](#jia225193-app-0002){ref-type="app"} *,* <https://github.com/winhiv/aavf-spec>). A tool suite to parse aavf format is available at <https://github.com/winhiv/PyAAVF>. The aavf file provides an amino acid variation summary, along with frequencies of relevant codons, across the examined region based on the associated NGS reads directly. It may serve as a generic variation report template from any NGS analysis   

  5\. General Analysis data management                                                        Data storage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Raw NGS data: to be stored by data generator while data analysis providers may transiently store it for reviewing purposeIntermediate files *(e.g. SAM, BAM)*: no need to storeVersioning data files for the applied pipeline: recommended                                                                                                                                                                                                                                                                                                                                                                                                     Automated versioning of all analysis results, reports and intermediate data files is required for retroactive data assessments when necessary

  Data disposal                                                                               Analysis provider disposes data after a defined holding period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Deposition of data into public archives (e.g. NCBI Sequence Read Archive) requires informed consent from the data generator                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Data ownership                                                                              Policy varies among different institutes and countriesClear data ownership statement should be included in Terms of Service and Conditions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        In general, data generators own all the data while unidentified data may be used by data analysis provider for evaluation or research purposes providing mutual agreement is in place                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DRM, drug resistance mutation; NGS, next‐generation sequencing; PBMC, peripheral blood mononuclear cell.
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"**NGS read QC/QA**" warrants that only high‐quality NGS reads are to be utilized in downstream HIVDR data analysis. Although all NGS platforms attach quality scores to individual basecalls, the additional NGS read QC/QA steps described in this consensus were deemed both necessary and effective in reducing false variant calling. Only basic read QC/QA strategies are described here and more stringent filtering may be required in certain cases."**NGS read alignment and reference mapping**" addresses the needs for valid and accurate read alignment to designated reference sequence(s) that enables subsequent variant calling. Pipelines should at minimum support reference mapping of the whole HIV *pol* gene, which encodes the three main drug‐targeted HIV enzymes: protease (PR), reverse transcriptase (RT) and integrase (IN). Although not urgently required for HIVDR genotyping, it would be beneficial for pipelines to also accommodate *full‐length* HIV reference alignment, since many users are adopting NGS for partial or full‐length HIV sequencing beyond the *pol* gene. Notably, genetic variability in the HIV *env* gene poses more challenges for reference alignment strategies than the relatively conserved *pol* gene. Certain insertions and deletions (indels) in HIV‐1 PR (near codon 35) and RT (near codon 69) genes are associated with drug resistance and such indels should be identified and reported for both HIVDR surveillance and clinical monitoring purposes [22](#jia225193-bib-0022){ref-type="ref"}, [23](#jia225193-bib-0023){ref-type="ref"}, [24](#jia225193-bib-0024){ref-type="ref"}, [25](#jia225193-bib-0025){ref-type="ref"}. Identification of such indels at the final HIVDR reporting stage is a relevant outcome of this alignment and reference mapping step. Indel management strategies differ among existing pipelines (Table [1](#jia225193-tbl-0001){ref-type="table"}). While several pipelines claim to accommodate indels in variant calling and DRM detection, pipelines that use NGS short‐read aligners such as bowtie2 [26](#jia225193-bib-0026){ref-type="ref"} may not adequately address such needs, since short‐read aligners cannot straightforwardly be used to capture the effect of indels on the resulting coding sequence. Other approaches that perform haplotype phasing or that incorporate codon‐aware alignment strategies may be needed to reliably detect known HIVDR‐associated indels, but further evaluation is needed."**HIV variant calling and variant QC**" imposes additional stringency on the calling of variants, which is especially important when minority variants are concerned. NGS errors may arise at multiple points during sample processing (e.g. nucleic acid extraction, reverse transcription, PCR, template amplicon preparation for NGS and NGS sequencing) and NGS data processing [27](#jia225193-bib-0027){ref-type="ref"}. The gross error rates generated from short‐read NGS platforms ranges from approximately 1 to 10 errors per 1000 bases leading to increased false positive detection of minority variants when their prevalence falls below approximately 1% [13](#jia225193-bib-0013){ref-type="ref"}, [28](#jia225193-bib-0028){ref-type="ref"}, [29](#jia225193-bib-0029){ref-type="ref"}, [30](#jia225193-bib-0030){ref-type="ref"}. The additional variant QC strategies significantly improve the reliability of calling variants of low abundance, undetectable by Sanger sequencing. It is acknowledged that the threshold of minority variant frequency considered to be clinically relevant remains debatable [31](#jia225193-bib-0031){ref-type="ref"}."**NGS HIVDR interpretation and reporting**" is the only component designed specifically for HIVDR application, while all other blocks and associated strategies may find broader application, especially for genomic sequence analysis of microbes harbouring high genomic diversity, similar to HIV. This specific element of the pipeline streamlines the strategies to convert valid NGS‐derived amino acid variant data into end‐user‐interpretable HIVDR results. Two HIVDR report formats are recommended in this Consensus for addressing needs of either research‐oriented projects (a *comprehensive report*) or clinically oriented testing (a *concise report*). Ultimately, a customizable HIVDR reporting strategy is preferred for an optimal pipeline, allowing the users to construct a report of their preference. To facilitate comparisons and merging of data from different pipelines, a new standard amino acid variant file (aavf) format has been proposed (Appendix [1](#jia225193-app-0002){ref-type="app"}, <https://github.com/winhiv/aavf-spec>). Based on the variant call format (vcf) standard that has been universally adopted for recording nucleotide variants, the aavf report provides a compact summary of the amino acid variation obtained by conceptual translation of the NGS read pileup across the examined region of the HIV genome. It also contains information on the frequencies of matching codons (wild type or mutant), quality of the variant calling as well as the coverage of relevant loci. Although the specification is designed to fully accommodate the requirements for reporting of NGS‐based HIVDR testing, it is still suitably generic to serve as a general purpose file format for reporting amino acid variants for broader applications. A tool suite to parse aavf format is available at <https://github.com/winhiv/PyAAVF>."**General analysis data management**" deals with issues that concern both the data generator and the analysis provider, to protect the best interests of both parties, including formats and contents for data storage, software versioning, information traceability and data ownership policies.

This symposium was held at a time when NGS for HIVDR genotyping is increasingly being adopted by many laboratories for research, surveillance and clinical monitoring purposes. Although the functionalities and assembly of bioinformatics strategies applied in different pipelines vary, they share a common objective. The Winnipeg Consensus addresses the urgent needs for and starts the process of standardization of NGS HIVDR data analysis pipelines. It is noteworthy that most of the bioinformatics strategies described in the Winnipeg Consensus have already been incorporated in three of the assessed pipelines, which explains the high concordance among these pipelines when the same data sets were analysed [32](#jia225193-bib-0032){ref-type="ref"}. Although minor differences currently exist among PASeq, HyDRA and MiCall regarding the data processing procedures and reporting strategies, preliminary data suggests that these pipelines are largely interchangeable especially when only HIVDR mutations present at ≥5% are of interest [32](#jia225193-bib-0032){ref-type="ref"}.

An additional important outcome of this symposium was a consensus that a well‐characterized NGS HIVDR "dry panel" should be constructed in support of both pipeline development and validation applications. Such a dry panel would consist of a variety of simulated data files as well as empirical data sets derived from plasmids, artificial plasmid mixtures and patient specimens. It should also cover all major HIV‐1 subtypes and signature DRMs at a wide range of frequencies, allowing the flexibility for end‐users to customize panels based on their needs. Such a comprehensive panel is currently under construction by the symposium participant teams and will become freely accessible to the public once established. In fact, a subset of the dry panel has already been used for a comparison of PASeq, HyDRA and MiCall [32](#jia225193-bib-0032){ref-type="ref"}.

Additional NGS HIVDR assay comparative assessment strategies, such as parallel testing of the same plasma specimens in different laboratories followed by analysis of the raw NGS data from each laboratory using all available pipelines, are also underway. This is in collaboration with the Virology Quality Assurance (VQA) programme supported by the Division of AIDS at the National Institutes of Health, USA, which provides quality assurance support for HIVDR laboratories worldwide [33](#jia225193-bib-0033){ref-type="ref"}.

It is acknowledged that some limitations exist in the Winnipeg Consensus, including: (1) it only addresses strategic issues concerning NGS data processing and subsequent report accuracy. Errors arising from pre‐analytical procedures remain to be minimized through comprehensive protocol validations [34](#jia225193-bib-0034){ref-type="ref"}; (2) strategies described here ensure the quality of minority variant detection and reporting based solely on the input NGS data, thus assuming that the applied NGS reads directly represent the intrahost viral quasispecies. Understandably, the sensitivity and accuracy of NGS in minority variant quantification are inherently dependent on the initial HIV RNA template input, which in turn is defined by specimen characteristics and assay designs such as viral load, specimen volume processed, fraction of extracted nucleic acids used for RT‐PCR, efficiency of RNA to DNA conversion and evenness of PCR amplification for HIV templates present in the specimen. Related accuracy limitations might be partially addressed using more sophisticated experimental designs such as primerID which is likely beneficial for research purposes, but not yet proven to be necessary for routine clinical use and hence not dealt with in this consensus [13](#jia225193-bib-0013){ref-type="ref"}, [35](#jia225193-bib-0035){ref-type="ref"}, [36](#jia225193-bib-0036){ref-type="ref"}, [37](#jia225193-bib-0037){ref-type="ref"}, [38](#jia225193-bib-0038){ref-type="ref"}; and (3) it was developed primarily based on processing of data from Illumina technology, which is currently the most widely used, but not the only platform for NGS HIVDR[39](#jia225193-bib-0039){ref-type="ref"}. Therefore, while Winnipeg Consensus principles apply to other NGS platforms, their exact implementation into data analysis pipelines will need to consider the platform‐specific characteristics and sequence error profiles for optimal results [20](#jia225193-bib-0020){ref-type="ref"}.

3. Conclusions {#jia225193-sec-0006}
==============

In conclusion, we present here the Winnipeg Consensus on bioinformatic strategies for NGS HIVDR data processing. This consensus may serve as an initial baseline to standardize NGS data analysis with a specific focus on HIVDR genotyping, and inform the refinement of existing pipelines and those still in development. This initiative and its subsequent activities may help make such technologies routine for both research and clinical HIVDR monitoring purposes, and may serve as a useful starting point for further developing of NGS analysis pipelines with similar and alternative intended applications.
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